We read with great interest the letter from Eguchi et al 1 providing additional evidence to support the lack of suitability of commercial antibodies for detecting angiotensin type-1 (AT 1 ) receptor protein in experimental systems. The data from Eguchi and associates extend our previous report 2 by documenting the failure of 2 additional antibodies to specifically detect rat AT 1 receptor protein in Western blots of protein isolated from cells transfected with rat AT 1 receptors fused with a hemagglutinin tag. Including Eguchi's letter and our study, there are now independent publications from 4 different laboratories demonstrating lack of specificity of 7 commonly used anti-AT 1 receptor antibodies available from reputable commercial sources [1] [2] [3] [4] (Table) . Indeed, it is notable that none of the antibodies tested have demonstrated specificity for AT 1 receptor protein. Thus, it is incumbent on investigators to verify the specificity and suitability of anti-AT 1 receptor antibodies for their particular experimental application. Reviewers and journals should likewise require such verification.
